Sara Comploj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sara Comploj has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anna Coppa
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
1 shared publication - Cecilia Midulla
Department of Molecular Medicine, Sapienza University, Rome 00161, Italy
1 shared publication - Emanuela Anastasi
Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, 00181 Rome, Italy
1 shared publication - Giuseppe Giannini
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
1 shared publication - Lucia Manganaro
Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00185 Rome, Italy
1 shared publication - Luigi Frati
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, 86077 Pozzilli, Italy
1 shared publication
Latest Publications
- Open Access
- 18 January 2011
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (1) , 627-632
HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report
Neoplasms of the ovary present an increasing challenge to the physician. Neoplastic ovarian cysts can resemble endometriomas in ultrasound imaging and need to be carefully considered in the differential diagnosis. We report the case of a woman with a strong family history of hereditary breast and ovarian cancer, who presented with a pelvic mass. The young girl refused oncogenetic counseling and genetic testing, even though she had a 50% a priori probability of being a BRCA1 mutation carrier. Pelvic magnetic resonance imaging (MRI) and a comparative analysis of the serum concentration of HE-4 and CA125 biomarkers provided accuracy and sensitivity in the diagnosis of a benign ovarian pathology. Based on this experience, we propose that the sensitivity of a screening program based on a HE4 and CA125 assay and MRI in high risk patients with mutations in the BRCA1 and BRCA2 genes may be considered a useful pre-operative tool for the differential diagnosis of pelvic masses.
- 18 January 2011
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (1) , 627-632
Open AccessHE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report
Neoplasms of the ovary present an increasing challenge to the physician. Neoplastic ovarian cysts can resemble endometriomas in ultrasound imaging and need to be carefully considered in the differential diagnosis. We report the case of a woman with a strong family history of hereditary breast and ovarian cancer, who presented with a pelvic mass. The young girl refused oncogenetic counseling and genetic testing, even though she had a 50% a priori probability of being a BRCA1 mutation carrier. Pelvic magnetic resonance imaging (MRI) and a comparative analysis of the serum concentration of HE-4 and CA125 biomarkers provided accuracy and sensitivity in the diagnosis of a benign ovarian pathology. Based on this experience, we propose that the sensitivity of a screening program based on a HE4 and CA125 assay and MRI in high risk patients with mutations in the BRCA1 and BRCA2 genes may be considered a useful pre-operative tool for the differential diagnosis of pelvic masses.